Literature DB >> 34322762

Alzheimer's disease: the controversial approval of Aducanumab.

Fabrizio Tagliavini1, Pietro Tiraboschi1, Antonio Federico2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34322762     DOI： 10.1007/s10072-021-05497-4

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  5 in total

Review 1.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

2.  Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease.

Authors:  James A R Nicoll; George R Buckland; Charlotte H Harrison; Anton Page; Scott Harris; Seth Love; James W Neal; Clive Holmes; Delphine Boche
Journal:  Brain       Date:  2019-07-01       Impact factor: 13.501

3.  The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.

Authors:  Jeff Sevigny; Ping Chiao; Thierry Bussière; Paul H Weinreb; Leslie Williams; Marcel Maier; Robert Dunstan; Stephen Salloway; Tianle Chen; Yan Ling; John O'Gorman; Fang Qian; Mahin Arastu; Mingwei Li; Sowmya Chollate; Melanie S Brennan; Omar Quintero-Monzon; Robert H Scannevin; H Moore Arnold; Thomas Engber; Kenneth Rhodes; James Ferrero; Yaming Hang; Alvydas Mikulskis; Jan Grimm; Christoph Hock; Roger M Nitsch; Alfred Sandrock
Journal:  Nature       Date:  2016-09-01       Impact factor: 49.962

4.  Controversial Alzheimer's drug approval could affect other diseases.

Authors:  Asher Mullard
Journal:  Nature       Date:  2021-07       Impact factor: 49.962

Review 5.  A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease.

Authors:  Francesco Panza; Bruno P Imbimbo; Madia Lozupone; Giancarlo Logroscino
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937
  5 in total
  4 in total

1.  The new therapy for Alzheimer's disease: from a hope for a few to a false hope?

Authors:  Stefania Orini; Cristina Geroldi; Orazio Zanetti
Journal:  Aging Clin Exp Res       Date:  2022-05-19       Impact factor: 3.636

Review 2.  Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?

Authors:  Serena Silvestro; Andrea Valeri; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2022-02-11       Impact factor: 5.923

3.  An Oligomannuronic Acid-Sialic Acid Conjugate Capable of Inhibiting Aβ42 Aggregation and Alleviating the Inflammatory Response of BV-2 Microglia.

Authors:  Jianrong Wu; Miaosen Wu; Hongtao Zhang; Xiaobei Zhan; Nian Wu
Journal:  Int J Mol Sci       Date:  2021-11-15       Impact factor: 5.923

4.  Plasma Phospho-Tau-181 as a Diagnostic Aid in Alzheimer's Disease.

Authors:  Ioanna Tsantzali; Aikaterini Foska; Eleni Sideri; Evdokia Routsi; Effrosyni Tsomaka; Dimitrios K Kitsos; Christina Zompola; Anastasios Bonakis; Sotirios Giannopoulos; Konstantinos I Voumvourakis; Georgios Tsivgoulis; George P Paraskevas
Journal:  Biomedicines       Date:  2022-08-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.